Introduction
Amyloid fibrils are built from proteins that form b-strands running perpendicularly to the fibril axis [1] [2] [3] [4] [5] . Although some amyloid fibrils are functional [6] [7] [8] [9] , they are also associated with several severe diseases, including neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) [1, 4, 10] . These neurodegenerative diseases are currently incurable and the available treatments only slow down the progression, and unpredictably some even show undesirable secondary effects [11, 12] . Amyloid fibrils associated with disease are formed when the amyloidogenic protein loses its native conformation and aggregates. Oligomeric species formed during the fibrillization process likely represent the most cytotoxic species while the mature fibrils are less toxic [13] [14] [15] [16] [17] . For amyloid b-peptide (Ab) associated with AD, the oligomers are mostly produced via secondary nucleation events that are catalyzed by the surface of the fibrils [18, 19] . Despite diverse primary structures, and also very different tertiary structures of the soluble state Abbreviations AD, Alzheimer's disease; Ab, amyloid b; CD, circular dichroism; ER, endoplasmic reticulum; HSQC, heteronuclear single quantum coherence; IMAC, immobilized metal affinity chromatography; NT, N-terminal domain; PD, Parkinson's disease; SEC, size exclusion chromatography; Spidroin, spider silk protein; TEM, transmission electron microscopy; ThT, thioflavin T.
[1], all amyloid proteins share common structural arrangements in the fibrils. The inherent aggregationprone nature of amyloidogenic proteins often makes them difficult to produce and purify. This renders experimental studies challenging and partly explains why the molecular mechanisms behind fibril formation are poorly understood.
Recombinant production of aggregation-prone proteins is particularly challenging due to the formation of aggregates and inclusion bodies that often require harsh conditions to solubilize [20] , which may have deleterious effects on protein function and structure. Solubility tags can sometimes prevent the formation of inclusion bodies by stabilizing the proteins during expression and enabling their purification under nondenaturing conditions [21] [22] [23] [24] . Inspired by how spiders store their very aggregation-prone silk proteins (spidroins) at high concentrations, we recently designed NT*, a solubility tag derived from the N-terminal domain (NT) of the Euprosthenops australis major ampullate spidroin 1 [25] . We used NT* as a solubility tag to successfully produce aggregation-prone peptides and proteins, including a lipophilic transmembrane peptide as a functional constituent of a synthetic lung surfactant, other surfactant proteins involved in innate immunity, and also the amyloid-forming Ab1-40 and Ab1-42 peptides [25] .
Herein, we investigate whether fusion to NT* can provide control over the aggregation of an amyloidogenic protein in order to allow for structural characterization of prefibrillar states as well as controlled studies of fibrillization. As an example of an amyloid-forming protein we chose b17, a de novo-designed polypeptide selected from a combinatorial library of synthetic proteins engineered to investigate amyloid aggregation [26] . The b17 protein was designed to form six b-strands containing seven amino acid residues each, separated by five short turns (Fig. 1) . The residues in each predicted strand were disposed in a polar/nonpolar pattern, as the amino acid periodicity rather than the amino acid composition seems to dictate b-sheet conformation [26, 27] . However, in contrast to a designed a-helical 'control' protein, for which the predicted structure has been confirmed by a determined NMR structure [28] , structural studies of b17 have been hampered by the low solubility and its tendency to aggregate already at rather low concentrations [26, 27] .
In eukaryotic cells, the toxicity of overexpressed b17 depends on its subcellular localization [27, [29] [30] [31] . Cytosolic aggregates are cytotoxic by sequestration of mainly disordered pre-existing proteins and newly synthesized proteins [27] . Aggregates directed to the nucleus exhibit a lower toxicity than the cytosolic aggregates, although they attenuate the nucleocytoplasmic transport by sequestering transport proteins [29] . Compared to the cytosolic aggregates, a significantly reduced toxicity was observed when b17 was directed to the endoplasmic reticulum (ER) [30, 31] .
In Escherichia coli (E. coli), b17 has previously been expressed in fusion to an N-terminal myc-tag for immunodetection, but the protein was insoluble and had to be purified from inclusion bodies by using triton and urea [26, 27] . Furthermore, in vitro studies of b17 fibril formation using refolded protein have been troubled with precocious aggregation [31] . Thus, there is a need to have a better control over b17 aggregation in order to facilitate in vitro studies of the mechanisms involved in amyloidogenesis.
In this study, we show that b17 is readily overexpressed in E. coli and highly soluble when fused to NT*. The tag keeps the amyloid-like protein unstructured and prevents it from aggregating. NT* enables studies of b17 aggregation, fibril formation, and structure. We demonstrate that salts and low pH favor the conversion of b17 from random coil to b-sheets and, thus, promote the aggregation of the polypeptide into amyloid-like fibrils.
Results
Expression and purification of NT*-b17 b17 was expressed as a fusion protein with NT* at its N-terminal end and the ability of NT* to promote solubility of b17 was assessed. The expression was performed overnight at 20°C in an E. coli BL21 strain and the 24 kDa NT*-b17 was expressed at a high level ( Fig. 2A) . To determine the solubility of the expressed protein, the cells were lysed with a cell disrupter and the lysate was centrifuged to separate the soluble and insoluble fractions. NT*-b17 was to a large extent present in the soluble fraction ( Fig. 2A) . The fusion protein was produced with an N-terminal His 6 tag to facilitate purification on a Ni-sepharose column followed by thrombin cleavage and a second column purification step to remove the solubility tag from the target protein. This approach yielded 166 mg of fusion protein and 53 mg of pure b17 per liter culture. The fusion protein could be concentrated up to 49 mgÁmL À1 (2 mM) without visual precipitation. Size exclusion chromatography (SEC) revealed that most of the fusion protein eluted with an apparent molecular weight of 50 kDa (Fig. 2B ). This may indicate the formation of a dimer, but considering that the b17 part is largely unstructured and that the fusion protein, thus, has a larger radius than expected from a compactly folded globule (see below); the elution profile is also compatible with a monomer.
Structural characterization of NT*-b17 and b17
To analyze the structure of the NT*-b17 fusion protein, 2D
H heteronuclear single quantum coherence (HSQC) NMR spectra were recorded at pH 7.5 to reduce amide hydrogen exchange with water but at the same time give a solubility comparable with that at pH 8.0. HSQC NMR experiments at low pH were not performed due to the reduced solubility of the fusion protein at pH below 6.8. The spectrum of the fusion protein at pH 7.5 looked similar to that of NT* alone, and only 18 new peaks compared to NT* were assigned (Fig. 2C) . Similar results were observed in the presence of physiological concentration of NaCl (data not shown). Given that the length of b17 together with the myc tag is 80 residues, only a minor part of the protein could be observed. The signal dispersion in the 1 H dimension was relatively small (0.6 ppm), indicating that the observed signals were from unstructured parts. 3D
15 N-resolved NOESY further revealed that the observed peaks belong to the linker region-including the myc tag-between NT* and b17 (residues S141 to E154) and the C-terminal region of b17 (residues G223 to H231) (Fig. 1) . 15 
N{
1 H} NOE experiment, which is sensitive to ps-to-ns timescale dynamics, confirmed that these regions are unstructured as manifested by the low I rel values (Fig. 2D) . Interestingly, the 15 N NMR relaxation analysis also showed that the rotational correlation time of NT* in fusion with b17 increased compared to NT* alone (data not shown), suggesting that NT* rotates as a larger structure (~20 kDa) than expected from its theoretical mass of 14.5 kDa (Fig. 2D) .
Heteronuclear single quantum coherence NMR measurement of released and purified b17 to detect changes in the structure upon the removal of the tag was not practical due to the long-handling times, and efforts to perform real-time measurement of b17 did not result in the appearance of additional peaks (data not shown). Instead, we used circular dichroism (CD) spectroscopy to determine the secondary structure of released b17. Thrombin cleavage of the fusion protein and subsequent removal of the tag on Nisepharose were performed rapidly with constant cooling and the purified b17 was immediately used for CD analysis at pH 6.0 and 8.0 (Fig. 3A) . At pH 8.0, the spectrum presented a strong negative peak at 200 nm and a small shoulder at 215 nm indicating a mainly random coil structure with some contributions from b-sheet structures. The spectrum recorded at pH 6.0, in contrast, showed features typical of a bsheet conformation. Hence, the conformation adopted by b17 is pH dependent, and a b-sheet secondary structure is favored at acidic pH. The fibril formation of released and purified b17 at pH 8.0 or pH 6.0 was evaluated by transmission electron microscopy (TEM). This showed mainly amorphous aggregates at both pH values but also short fibrils at pH 6.0 (Fig 3B-C) .
NT* controls the fibrillization of b17
The aptitude of NT* to control b17 fibrillization was measured by fibril formation kinetic assay using the amyloid binding dye Thioflavin T (ThT) as a reporter ( Fig. 4A-B) . The fluorescence intensity of NT* or thrombin alone was kept at baseline, showing that neither the solubility tag nor the protease bind ThT (data not shown). Similarly, the fluorescence intensity of NT*-b17 was maintained at baseline over several hours (Fig. 4A) Fig. 1 . Amino acid sequence of NT*-b17. The His 6 affinity purification tag is shown in yellow, NT* is shown in gray, the myc tag is underlined, and b17 is shown in green. b17 predicted b-strands (green arrows) are separated by turns (red). The amino acid residues assigned by NMR spectroscopy are shown in bold.
precipitates and no fibrils were observed (Fig. 4C ). When NT*-b17 was cleaved by thrombin, formation of fibrils was observed after a relatively short lag phase (Fig. 4A ). These results suggest that when released from the tag, b17 assembles into ThT-positive amyloid fibrils as revealed by TEM (Fig. 4D) . A tightly controlled system for aggregation of amyloid proteins is of interest for the evaluation of compounds that can interfere with fibril formation. The Bri2 BRICHOS domain, for example, has been suggested to act as an anti-amyloid chaperone by delaying Ab1-42 fibrillization [32, 33] . ThT kinetic assays showed that the Bri2 BRICHOS domain inhibits b17 fibril formation in a dose-dependent manner (Fig. 4B) . 
Calcium favors b17 fibril formation
In eukaryotic cells, b17 formed inclusions in the ER but showed no toxicity [30, 31] , whereas cell viability was impaired to a significant extent when the protein formed fibrils in the cytosol [27, 31] . We hypothesized, therefore, that the higher concentration of calcium in the ER than in the cytosol might be a factor that contributes to these different behaviors. To test this hypothesis, ThT kinetic assays were performed using the NT*-b17/thrombin system, after incubation in the absence or in the presence of 0.3-2.5 mM CaCl 2 . The experiments were only performed at pH 8.0 to ensure that the observed effects were due to the added salt and not promoted by a lowered pH. This showed that the b17 fibrillization rate and the ThT fluorescence starting amplitude increased with increasing calcium concentrations (Fig. 5A) , suggesting that calcium favored the formation of ThT-positive aggregates before the start of measurements and/or that the fibrillization occurred in an ultrafast manner after the addition of thrombin. Analysis of the samples by TEM confirmed the formation of fibrils (Fig. 6A-D) . Moreover, the fibrils became more abundant when the calcium concentration was increased. Measurements in the presence of MgCl 2 instead of CaCl 2 but otherwise using the same conditions showed a similar fibril formation kinetic profile (Fig. 5B) and TEM images revealed the presence of a large number of fibrils (Fig. 6E) . We evaluated the effect of monovalent ions on fibrillization by incubating b17 in the presence of physiological concentration of NaCl. Although fibril formation kinetic assay suggests the formation of fibrils (Fig. 5C ), few fibrils and numerous amorphous aggregates were observed with TEM (Fig. 6F) . To verify that calcium stabilizes the b-sheet conformation of b17, CD measurements were performed at pH 8.0 in the presence of 0.3-40 mM Ca(CH 3 COO) 2 . Increasing concentrations of calcium shifted the negative peak from 200 nm to 214 nm, suggesting that calcium promotes a structural conversion from random coil to b-sheet (Fig. 5D) . The plot of ellipticity minimum wavelength vs calcium concentration shows a sigmoidal transition with a midpoint at 6.3 mM (Fig. 5E ).
Discussion
We studied NT* as tool for production and experimental studies of amyloid fibril-forming proteins, using the 
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The FEBS Journal 285 (2018) 1873-1885 ª 2018 Federation of European Biochemical Societies de novo-designed protein b17. NT* mediates the production of high amounts of b17 in E. coli and also enables the purification of monomeric soluble b17 without the use of denaturants or detergents. NT* may be used for the production and studies of other amyloid proteins such as, for example, Ab1-42, which can be produced at high yields in fusion with NT* [25] . Amyloidogenic peptides can be chemically synthesized [34, 35] , but this is expensive and not possible for larger proteins. Recombinant expression represents an alternative [36] [37] [38] [39] [40] [41] , but the expressed proteins should preferably be kept soluble to avoid harsh conditions for renaturation. For example, a-synuclein is purified from inclusion bodies by heat denaturation, and this yields a mixture of the full-length and partially degraded protein [36] [37] [38] [39] [40] [41] [42] . In contrast, the NT* method is efficient and involves only nondenaturing conditions. Moreover, NT* not only gives high yields of soluble b17 but also provides control over b17 aggregation and enables structural and fibrillization studies using NMR and CD spectroscopy and ThT kinetic assays. ThT fluorescence shows that NT*-b17 is unable to assemble into b-sheet fibrils. To our knowledge, previous in vitro studies of b17 have not reported fibrillization kinetics; only end point measurements [26, 27, 31] possibly due to precocious aggregation. Interestingly, the tight control over b17 aggregation allows interaction studies with amyloidbinding proteins. ThT kinetic assays showed reduced fluorescence intensity, when b17 was incubated in the presence of Bri2 BRICHOS compared to b17 alone, suggesting that b17 fibrillization was inhibited (Fig. 4B) . These results are in accordance with the versatile antiaggregation properties described for different Bri2 BRI-CHOS species, which include reduction in amyloid-like fibril formation and toxicity as well as interference with nonfibrillar aggregation of destabilized protein [32] .
Only a fraction of expected b17 signals were detected in the HSQC spectrum of NT*-b17, possibly due to conformational exchange between a monomeric form and a larger structure. The latter may represent a dimeric form of the fusion protein as supported by the hydrodynamic radius observed with SEC (Fig. 2B) . Moreover, also the long rotational correlation time recorded for NT* using HSQC NMR is consistent with the molecular weight of a larger structure, implying that the b17 and NT* parts of the fusion protein weakly interact. The interaction might be electrostatic since both parts have charged regions on their surface. Altogether, HSQC NMR data suggest that b17 mainly is kept unstructured in fusion with NT* but has a tendency to form dimers or small aggregates. Our results for b17 are thus in accordance with structural studies of the disease-related amyloid-forming proteins a-synuclein and Ab, which are monomeric and disordered in solution [43] [44] [45] [46] . We also showed that b17 can be readily cleaved off from NT*, which allows structural studies and investigation of the aggregation process. West and coworkers designed b17 to adopt a b-sheet secondary structure [26] and b17 was reported to form b-sheets and to assemble into fibrils at pH 8.0 in the presence of salts [26, 27] . Our results show that b17 is mainly in a random coil conformation at pH 8 in the absence of salts but converts to a b-sheet conformation in the presence of calcium (Fig. 5D) . CD spectroscopy revealed that b17 forms b-sheets at pH 6 (Fig. 3A) , indicating that also an acidic environment promotes conversion into b-sheets. The rationale behind this observation is that protonation at acidic pH can promote fibril formation by relieving negative charge repulsions and providing new inter-and intramolecular hydrogen bond interactions. Conversion into b-sheet structure is expected to facilitate the formation of amyloid-like fibrils, and in agreement with our results, Olzscha and coworkers [27] found that b17 forms long and thick fibrils at pH 6.0 but only short and thin filaments at pH 8.0. It is known that many amyloidogenic proteins and peptides can form fibrils with varying morphologies depending on conditions, and therefore, direct comparison is complicated by experimental differences. The thin filaments observed by Olzscha and coworkers at high pH can be explained by the presence of MgCl 2 in their samples. Moreover, the incubation times were not reported and differences in handling time may have consequences on the fibril physical appearance.
b17 was reported to form nonamyloid inclusions in the ER [30, 31] and to aggregate into fibrils in the cytosol [27, 31] . We hypothesized that the higher calcium concentration in the ER might affect b17 conformation and favor its aggregation into nontoxic inclusions. Indeed, calcium promotes b-sheet conversion and markedly accelerates the formation of ThT-positive aggregates in vitro, and a similar effect on fibril formation kinetics was observed in the presence of magnesium (Figs. 5 and 6 ). It has been shown that fibril formation of the human protein Pmel is ultrafast and that this can be a means to avoid formation of cytotoxic species [7] . We suggest that the high calcium concentration in the ER can promote very fast fibril formation of b17 and thereby reduce its ability to form toxic intermediates. Our results are in accordance with the reports showing that Ab1-40 [47] and insulin [48] aggregations are promoted by various salts, and a-synuclein aggregation is accelerated by calcium [49] . The mechanisms by which salts promote aggregation are not well understood. The salt might affect aggregation by the Debye-H€ uckel effect, that is, the ions shield the charged residues. At pH 8, b17 is strongly negatively charged with a theoretical net charge of À10. Hence, the repulsive interactions, generated by the negatively charged residues, might be reduced in the presence of salts and might make b17 more aggregation prone as intermolecular associations are favored.
Interestingly, the b17 fibrils show different morphologies depending on the concentration and the type of salt used (Fig. 6) . The highest concentration (2.5 mM) of calcium used in ThT kinetic assay gave the largest number of well-structured fibrils (Fig. 6A-D) , similar to the effect of 2.5 mM MgCl 2 (Fig. 6E) . In contrast, sodium led to the formation of mainly amorphous structures together with a limited number of fibrils (Fig. 6F) . This indicates that b17 fibril formation is promoted by divalent cations, while monovalent cations promote nonfibrillar aggregation. Calcium and magnesium coordinate more water molecules than sodium and given the large number of negative charges in the protein; stronger electrostatic interactions of the protein with the divalent cations than with the monovalent cations are expected. Divalent cations might thus promote stronger protein-protein interactions leading to more efficient formation of fibrils than monovalent ions.
In conclusion, our findings suggest that fusion to NT* enhances b17 recombinant expression and solubility by keeping it in a largely monomeric state for a prolonged time. Controlled amyloid fibril formation of b17 by proteolytic release from NT* allowed studies of effects of pH and salts, which suggest that different local intracellular concentrations of calcium may contribute to the previous findings of varying toxicity of b17 depending on what cellular compartment the protein is targeted to.
Materials and methods

Subcloning of b17
A HiFi HotStart DNA polymerase (Kapa Biosystems, Wilmington, MA, USA) was used for PCR amplification, from a previously constructed vector containing the mycb17 gene. The gene was amplified with a 60°C annealing temperature using the sense primer 5 0 -ATATTGAA TTCCCTGGTGCCACGC GGTTCTATGGGCGAACAG AAGTTAA-3 0 and the antisense primer 5 0 -GGCT CGGGTGCCAAGCTTTTAATGCATTTTCACTTCAAC ATCAC-3 0 . The PCR product was cleaved with restriction enzymes EcoRI and HindIII (Thermo Fisher Scientific, Waltham, MA, USA) and ligated into the vector pT7His-NT* that was previously digested with the same enzymes.
The new construct was transformed to E. coli Nova Blue chemically competent cells by heat shock transformation.
Plasmids were prepared using QIAprep Spin Miniprep Kit (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations and were sent for sequencing to verify the correct sequence of the inserted fragment.
Expression of NT*-b17
The NT*-b17 plasmid was used to transform chemically competent E. coli BL21 (DE3) cells. An overnight culture was inoculated 1/100 to Luria-Bertani medium containing kanamycin (70 mgÁL À1 ) and grown at 30°C to an OD 600 of 0.9. The culture was then induced by addition of IPTG to a final concentration of 0.5 mM and was further incubated overnight at 20°C. The cells were harvested by centrifugation at 5000 g for 20 min, resuspended to 40 mL in 20 mM Tris-HCl pH 8.0 (loading buffer), and stored at À20°C overnight. The cells were thawed and lysed in a cell disrupter (T-S Series Machine, Constant Systems Limited, Daventry, Northants, UK) at 30 kPsi. The lysate was cleared by centrifugation at 24 000 g for 30 min. Analysis of the cleared lysate and the remaining pellet to assess protein solubility was performed by SDS/PAGE in a 15% polyacrylamide gel, stained with Coomassie brilliant blue.
Purification of b17
The supernatant after lysis was loaded onto an immobilized metal affinity chromatography (IMAC) column packed with Ni-Sepharose (GE Healthcare, Uppsala, Sweden) and equilibrated with loading buffer. The column was washed with 10 mM imidazole, 20 mM Tris-HCl, pH 8, and bound protein was eluted in 1 mL fractions using 300 mM imidazole, 20 mM Tris-HCl, pH 8. The absorbance at 280 nm was measured for each fraction, and protein-containing fractions were pooled. Dialysis was performed using a Spectra/Por Ò dialysis membrane (6-8 kDa molecular weight cutoff; Spectrum Laboratories, Rancho Dominguez, CA, USA) incubated overnight in 5 L of loading buffer. The correct size of the protein was confirmed by SDS/ PAGE in a 15% polyacrylamide gel, stained with Coomassie brilliant blue dye.
Centrifugal filter concentration
Purified NT*-b17 protein was concentrated by ultrafiltration to determine the concentration limit. The protein at a concentration of 6 mgÁmL À1 was concentrated at 4000 g and at 4°C in a Vivaspin 6 centrifugal tube with a 10 kDa molecular weight cutoff (GE Healthcare). The final protein concentration was determined from the absorbance at 280 nm.
Nuclear magnetic resonance spectroscopy
All NMR experiments were performed at 25°C on a Varian Unity Inova 600-MHz NMR spectrometer equipped with an HCN triple-resonance pulsed-field gradient cold probe. The 2D 15 N -1 H HSQC spectra were acquired for a sample containing 0.5 mM NT*-b17, 10 mM Tris-HCl (pH 7.5), 7% (v/v) D 2 O in the presence and absence of 150 mM NaCl. The 3D 15 N-resolved NOESY-HSQC spectrum was recorded with 100 ms mixing time using a sample in 20 mM sodium phosphate buffer at pH 6.8. All spectra were processed with Bruker TopSpin 3.5 (Bruker, MA, USA) and analyzed in the freeware CARA. 15 N heteronuclear NOE and relaxation data of NT*-b17 were recorded at pH 7.5. [52] . The spectra were processed using Topspin 3.5 (Bruker) and NMRPipe [53] . Relaxation data were analyzed with software RELAX [54] .
Size exclusion chromatography
Size exclusion chromatography was performed on an € AKTA TM basic 10 system with UV detection at 280 nm, using a Superdex-200 column (GE Healthcare), and a flow rate of 0.5 mLÁmin
À1
. 200 lL samples of 2 mgÁmL À1 protein solutions were injected and the column was equilibrated with running buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8) before each run. A molecular mass standard set consisting of cystatin (13 kDa), carbonic anhydrase (29 kDa), and antithrombin (58 kDa) was chromatographed to estimate the apparent molecular weight of the fusion protein.
Circular dichroism spectroscopy
The tag was cleaved off by 1/100 (w/w) thrombin for 20 min on ice followed by a reverse IMAC purification where unbound b17 protein was collected in 1 mL fractions using ice-cold 5 mM Tris-HCl, pH 8. The absorbance at 280 nm was measured for each fraction, and protein-containing fractions were pooled. Part of the sample was subjected to gel filtration on a PD-10 column (GE Healthcare) in order to exchange the buffer for ice-cold 5 mM sodium phosphate at pH 6.0 or 8.0. Experiments were performed on a Chirascan TM V100 CD spectrometer (Applied Photophysics Limited, Leatherhead, Surrey, UK) using 300 lL cuvettes with 1 mm path length. For all measurements, the purified b17 was diluted to 10 lM either in 5 mM Tris-HCl, pH 8.0 with 0.3 mM, 0. kanamycin, and the cells were incubated at 30°C. At an OD 600 around 0.9, the incubation temperature was lowered to 20°C, IPTG was added to 0.5 mM and the cells were incubated overnight. The cells were then harvested by centrifugation at 5000 g at 4°C, after which the cell pellet was resuspended in 20 mM Tris-HCl pH 8.0 and sonicated for 5 min on ice (2 s on, 2 s off, 65% of maximum power). The lysate was centrifuged (50 000 g) at 4°C for 30 min and the supernatant containing the fusion protein was then loaded on a Ni-Sepharose column. Unbound proteins were washed away and the fusion protein was eluted with 300 mM imidazole, and then dialyzed overnight against 20 mM Tris-HCl pH 8.0 at 4°C. To remove the His 6 -NT* part, the fusion protein was cleaved with thrombin (1/1000 enzyme to substrate, w/w) at 4°C overnight and loaded over a Ni-Sepharose column.
Thioflavin T kinetic assay
Fibrillization kinetics were studied by measuring the ThT intensity of fluorescence over time with a POLARstar Ò Omega spectrofluorometer (BMG Labtech, Cary, NC, USA). The fluorescence was recorded using Nunc TM 384-well black polystyrene microplates with clear bottom (Corning Incorporated, Corning, NY, USA). 100 lM of NT*-b17 was kept on ice, in the absence or in the presence of 1/1000 (w/w) thrombin and was supplemented with 10 lM of ThT reporter from a 1 mM stock solution. The sample was incubated without salt, in 0.3 mM, 0.6 mM, 1.25 mM, and 2.5 mM CaCl 2 or MgCl 2 , or in 154 mM NaCl or with BRICHOS at a 1 : 4, 1 : 2, and 1 : 1 BRICHOS/ NT*-b17 ratio. Ice-cold samples were added to each well and the plate was immediately placed in the plate reader. The samples were excited at 440 nm (bandwidth 10 nm) and emission spectra were taken at 480 nm (bandwidth 10 nm) every 1.5 min for 20 h at 37°C under quiescent condition. The spectra recorded in the presence of Bri2 BRICHOS were normalized according to their baseline.
Transmission electron microscopy b17 was released from the tag by incubation in the presence of 1/100 (w/w) thrombin for 20 min at 4°C followed by a reverse IMAC purification. Unbound b17 protein was collected in 1 mL fractions using 20 mM Tris-HCl, pH 8.0. The absorbance at 280 nm was measured for each fraction, and protein-containing fractions were pooled. Part of the sample was subjected to gel filtration on a PD-10 column (GE Healthcare) in order to exchange the buffer for 20 mM HEPES at pH 6.0 or 8.0. TEM grids were prepared from samples incubated for 20 h at 37°C. b17 was incubated at pH 6.0 or at pH 8.0 and NT*-b17 was incubated in the presence of 1/1000 (w/w) thrombin without salt or in the presence of 0.3, 0.6, 1.25, and 2.5 mM CaCl 2 , 2.5 mM MgCl 2 , or 154 mM NaCl. Small volumes (3 lL) of samples were deposited on glow-discharged, carbon-coated copper grids. After incubating the samples on grids at room temperature for one minute, excess liquid was blotted away by filter paper and the grids were washed in two drops of water before staining them for 30 s in 2% aqueous solution of uranyl acetate (TAAB Laboratories Equipment, Aldermaston, Berkshire, UK). Air-dried specimens were checked in a JEM-2100f electron microscope (JEOL, Tokyo, Japan) operated at 200 kV, using a 4k 9 4k CCD camera (TemCam-F415, TVIPS, Gauting, Germany). Images were recorded with nominal magnifications 50 000 and 60 000 using 1.0-1.5 lm defocus values.
